1. Home
  2. SYBX vs CYCU Comparison

SYBX vs CYCU Comparison

Compare SYBX & CYCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • CYCU
  • Stock Information
  • Founded
  • SYBX N/A
  • CYCU N/A
  • Country
  • SYBX United States
  • CYCU United States
  • Employees
  • SYBX N/A
  • CYCU N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • CYCU
  • Sector
  • SYBX Health Care
  • CYCU
  • Exchange
  • SYBX Nasdaq
  • CYCU Nasdaq
  • Market Cap
  • SYBX 13.6M
  • CYCU 13.1M
  • IPO Year
  • SYBX N/A
  • CYCU N/A
  • Fundamental
  • Price
  • SYBX $1.26
  • CYCU $0.37
  • Analyst Decision
  • SYBX
  • CYCU
  • Analyst Count
  • SYBX 0
  • CYCU 0
  • Target Price
  • SYBX N/A
  • CYCU N/A
  • AVG Volume (30 Days)
  • SYBX 7.8K
  • CYCU 1.8M
  • Earning Date
  • SYBX 08-07-2025
  • CYCU 06-06-2025
  • Dividend Yield
  • SYBX N/A
  • CYCU N/A
  • EPS Growth
  • SYBX N/A
  • CYCU N/A
  • EPS
  • SYBX 0.21
  • CYCU N/A
  • Revenue
  • SYBX N/A
  • CYCU $17,398,680.00
  • Revenue This Year
  • SYBX N/A
  • CYCU N/A
  • Revenue Next Year
  • SYBX N/A
  • CYCU N/A
  • P/E Ratio
  • SYBX $5.82
  • CYCU N/A
  • Revenue Growth
  • SYBX N/A
  • CYCU N/A
  • 52 Week Low
  • SYBX $0.90
  • CYCU $0.26
  • 52 Week High
  • SYBX $1.88
  • CYCU $10.99
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 52.81
  • CYCU N/A
  • Support Level
  • SYBX $1.17
  • CYCU N/A
  • Resistance Level
  • SYBX $1.27
  • CYCU N/A
  • Average True Range (ATR)
  • SYBX 0.04
  • CYCU 0.00
  • MACD
  • SYBX -0.01
  • CYCU 0.00
  • Stochastic Oscillator
  • SYBX 40.00
  • CYCU 0.00

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About CYCU Cycurion Inc. Common Stock

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

Share on Social Networks: